Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAPSID: GLP-1 Analogues for Steroid-Induced Diabetes
NCT06318442Recruiting
- Sponsor
- Imperial College London
- Start
- May 2024
- Primary completion
- Jun 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of semaglutide in steroid-induced diabetes (3 arms), sponsored by Imperial College London. Primary endpoint: Glucose tolerance in response to standardised mixed meal test at Day 7. Started May 2024; status: recruiting.
02
Drugs
03
Conditions
steroid-induced diabetes
Beyond the preview
Go deeper on NCT06318442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06318442.